Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Daiichi Sankyo announces Factor Xa inhibitor results

Daiichi Sankyo announces Factor Xa inhibitor results

3rd September 2008

Daiichi Sankyo has announced clinical study data for its oral Factor Xa inhibitor DU-176b at the annual congress of the European Society of Cardiology.

The results showed the compound reduced the incidence of venous thromboembolism in elective unilateral hip replacement surgery patients when compared to dalteparin.

Observed bleeding rates were low across the groups while there was a statistically significant dose response in efficacy.

The study assessed the safety and efficacy of four doses of the compound compared to low molecular weight heparin in 903 patients in Europe and North America.

Gary Raskob, dean of the College of Public Health at the University of of Oklahoma Health Sciences Centre, said: “These findings are encouraging and we look forward to further study on this Factor Xa inhibitor.”

He added that the study results suggest the compound may offer a high degree of efficacy, but noted further studies are needed to confirm these findings.

Daiichi Sankyo said it expected to start phase III studies for the compound in patients with atrial fibrillation before the end of 2008.

Earlier this week, Daiichi Sankyo and Eli Lilly announced positive results of a head-to-head study comparing prasurgrel with clopidogrel in diabetes patients.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.